Copy
CANCER CLINICAL TRIALS NEWSLETTER

This is a study for newly diagnosed, B-Cell Acute lymphoblastic leukemia evaluating the efficacy of the addition of Inotuzumab Ozogamicin to frontline therapy in young adults. Efficacy will be determined by measuring the rate of Event Free Survival. This study has two separate components: an upfront tolerability confirmation portion and then a full phase III evaluation of the two treatment regimens. 

In the phase III evaluation, patients in Arm 1 will undergo frontline chemotherapy alone. Arm 2 participants will also receive Inotuzumab Ozogamicin via IV infusion on Days 1, 8, and 15 of each 28 day cycle. The last day of each cycle, bone marrow aspiration and biopsy will be performed for disease assessment. 




(A041501, IRB 2020-0014)

MK7902-012
IRB 2020-0135
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma
Amgen 20190135
IRB 2020-0194
A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

Our phone-based research recruitment app has features updates and a new look! It is available to all UC Cancer Center members and outside colleagues to aid in patient recruitment into cancer and other research studies.

Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? The UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all UC and non-UC referring providers. The new app allows for the entire recruiting portfolio of UC Cancer Center studies to always be updated by the research team. For each study, a summary, inclusion and exclusion criteria, other pertinent study information, and a “one-touch” contact button for the primary research coordinator are included

It takes only seconds to get the new app. On your phone, simply go to https://ctra.highenroll.org. Add the app to your home screen for quick and easy use.  Please delete all other prior versions of the app. 

If you have any questions, please research out to your UC Cancer Center research team or High Enroll members, Dr. Dylan Steen @ 908-208-6927, dlsteen@highenroll.org or Ginger Conway @859-992-5339, gaconway@highenroll.org.

 

 Thanks,

Dylan and Ginger

https://uc.us20.list-manage.com/track/open.php?u=6e0c6353f4d0cff892fa85067&id=17c04815d2&e=e50cd33d0c

UC study: Cancer, COVID-19 and blood clots

UC researcher receives a grant to investigate how cancer therapy could impact COVID-19 patients.  A UC Oncologist is studying how treatments for patients with cancer and COVID-19 could cause other health complications, namely blood clots. They recently received a $25,000 grant from the North American Thrombosis Forum to help her investigate this problem.


Click Here to Visit the UC Newsroom
University of Cincinnati Cancer Center Symposium on Tumor Microenvironment 2020

Friday, Oct. 16, 2020  | 9:00 a.m.- 2:00 p.m

Virtual Event Access: TMSymposium.provirtualevent.com


For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.

View Flyer as PDF
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
CANCER CLINICAL TRIALS NEWSLETTER
Questions?  Please call us at 513-584-7698, or email us!
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA